CD8A and prostate cancer: Upregulated PD-L1 expression in prostate cancer cells upon BAY-I treatment may counteract the cytotoxic activity of CD8+ T cells, which provided clear rationale for testing anti-PD-1 combination therapy to achieve maximum tumor killing effect.